23 patents
Utility
FC Binding Fragments Comprising a PD-L1 Antigen-binding Site
21 Dec 23
The application relates to specific binding members which bind to programmed death-ligand 1 (PD-L1).
Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev
Filed: 8 Dec 22
Utility
Multivalent immunoglobulins
28 Nov 23
The present invention provides a multivalent immunoglobulin or part thereof binding specifically to at least two cell surface molecules of a single cell with at least one modification in at least one structural loop region of the immunoglobulin determining binding to an epitope of the cell surface molecules wherein the unmodified immunoglobulin does not significantly bind to the epitope, its use and methods for producing it.
Florian Ruker, Gottfried Himmler, Gordana Wozniak-Knopp
Filed: 15 Aug 17
Utility
Egfr Binding Molecules
9 Nov 23
The application relates to specific binding members which bind the human epidermal growth factor receptor (EGFR).
Mihriban Tuna, Kin-Mei Leung, Haijun Sun, Melanie Medcalf, Samine Isaac
Filed: 8 Feb 23
Utility
Synthetic Immunoglobulin Domains with Binding Properties Engineered In Regions of the Molecule Different from the Complementarity Determining Regions
26 Oct 23
Libraries of immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind.
Gottfried Himmler, Florian Ruker, Gordana Wozniak-Knopp
Filed: 11 Oct 22
Utility
Compounds,compositions, and methods for the treatment of disease
5 Sep 23
Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.
Radhakrishnan P. Iyer, Anjaneyulu Sheri, Seetharamaiyer Padmanabhan, Geeta Meher, Shenghua Zhou, Sreerupa Challa, Rayomand H. Gimi, Dillon Cleary
Filed: 4 Jun 21
Utility
Compounds, Compositions, and Methods for the Treatment of Disease
31 Aug 23
Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.
Radhakrishnan P. Iyer, Geeta Meher, Anjaneyulu Sheri, Shenghua Zhou, Sreerupa Challa, Rayomand H. Gimi, Seetharamaiyer Padmanabhan, Dillon Cleary
Filed: 20 Jan 23
Utility
Compounds, compositions, and methods for the treatment of disease
25 Jul 23
Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.
Radhakrishnan P. Iyer
Filed: 11 Sep 18
Utility
Compounds, compositions, and methods for the treatment of disease
2 May 23
Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.
Radhakrishnan P. Iyer, Anjaneyulu Sheri, Geeta Meher, Sreerupa Challa, Shenghua Zhou
Filed: 30 Aug 18
Utility
EGFR binding molecules
18 Apr 23
The application relates to specific binding members which bind the human epidermal growth factor receptor (EGFR).
Mihriban Tuna, Kin-Mei Leung, Haijun Sun, Melanie Medcalf, Samine Isaac
Filed: 19 Jul 17
Utility
Compounds, compositions, and methods for the treatment of disease
21 Feb 23
Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.
Radhakrishnan P. Iyer, Geeta Meher, Anjaneyulu Sheri, Shenghua Zhou, Sreerupa Challa, Rayomand H. Gimi, Seetharamaiyer Padmanabhan, Dillon Cleary
Filed: 11 Sep 18
Utility
FC binding fragments comprising a PD-L1 antigen-binding site
10 Jan 23
The application relates to specific binding members which bind to programmed death-ligand (PD-L1).
Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev
Filed: 19 Dec 18
Utility
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
15 Nov 22
Libraries of immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind.
Gottfried Himmler, Florian Ruker, Gordana Wozniak-Knopp
Filed: 22 Nov 19
Utility
Dosage Regimes for the Administration of a LAG-3/PD-L1 Bispecific Antibody
1 Sep 22
The application relates to dosage regimes for the administration of an antibody molecule which binds programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3) and their medical use in the treatment of cancer in human patients.
Michelle Morrow, Fiona Germaschewski, Daniel Gliddon, Kin-mei Leung, Cristian Gradinaru, Christopher Shepherd, Josefin-Beate Holz, Louis Kayitalire
Filed: 14 May 20
Utility
Binding Molecules Binding PD-L1 and LAG-3
16 Jun 22
The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3).
Jamie Campbell, Nikole Sandy, Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Mustapha Faroudi, Natalie Fosh, Barbara Hebeis
Filed: 23 Nov 21
Utility
LAG-3 Binding Members
16 Jun 22
The present invention relates to specific binding members which bind to lymphocyte-activation gene 3 (LAG-3).
Mihriban Tuna, Francisca Wollerton, Katy Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Natalie Fosh
Filed: 23 Nov 21
Utility
Compounds, Compositions, and Methods for the Treatment of Disease
2 Jun 22
Disclosed are compounds and compositions for inhibiting the expression of a pattern recognition receptor (e.g., STING), and methods of use thereof.
RADHAKRISHNAN P. IYER, SEETHARAMAIYER PADMANABHAN, SUBRAMANIAN BASKARAN, ANJANEYULU SHERI, DILLON CLEARY, RON MASTROLIA, SHENGHUA ZHOU, SREERUPA CHALLA, RAYOMAND H. GIMI, VISHAL NAIR, LEENA PRABA SUPPIAH
Filed: 5 Mar 20
Utility
Compounds,compositions, and Methods for the Treatment of Disease
24 Feb 22
Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.
Radhakrishnan P. Iyer, Anjaneyulu Sheri, Seetharamaiyer Padmanabhan, Geeta Meher, Shenghua Zhou, Sreerupa Challa, Rayomand H. Gimi, Dillon Cleary
Filed: 4 Jun 21
Utility
Compounds, Compositions, and Methods for the Treatment of Disease
7 Oct 21
Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.
Radhakrishnan P. Iyer, Geeta Meher, Sreerupa Challa, Shenghua Zhou
Filed: 8 Jul 19
Utility
Compounds, Compositions, and Methods for the Treatment of Disease
8 Jul 21
Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.
Radhakrishnan P. Iyer, Anjaneyulu Sheri, Geeta Meher, Sreerupa Challa, Shenghua Zhou
Filed: 30 Aug 18
Utility
Compounds,Compositions, and methods for the treatment of disease
15 Jun 21
Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.
Radhakrishnan P. Iyer, Anjaneyulu Sheri, Seetharamaiyer Padmanabhan, Geeta Meher, Shenghua Zhou, Sreerupa Challa, Rayomand H. Gimi, Dillon Cleary
Filed: 6 Jul 17